Dynavax Technologies

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 408

Market Cap: $1.4B

Website

Introduction: Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Clinical Trials

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults

Phase 1

Recruiting

Conditions: Shingles
Vaccine-Preventable Diseases
Herpes Zoster

Interventions: Biological: Z-1018
Biological: Shingrix

First Posted Date: 2024-08-26

Last Posted Date: 2024-08-26

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 440

Registration Number: NCT06569823

Locations: 🇦🇺
Northern Beaches Clinical Research, Brookvale, New South Wales, Australia

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Phase 2

Completed

Conditions: Plague
Vaccine-Preventable Diseases
Plague, Pneumonic

Interventions: Biological: rF1V vaccine
Biological: rF1V vaccine and CpG 1018® adjuvant

First Posted Date: 2022-08-18

Last Posted Date: 2024-05-23

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 200

Registration Number: NCT05506969

Locations: 🇺🇸
Optimal Research Alabama, Huntsville, Alabama, United States
🇺🇸
Optimal Research Illinois, Peoria, Illinois, United States
🇺🇸
Optimal Research Maryland, Rockville, Maryland, United States

and more 3 locations

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Shingles
Vaccine-Preventable Diseases
Herpes Zoster

Interventions: Biological: Z-1018
Biological: Shingrix

First Posted Date: 2022-02-18

Last Posted Date: 2022-11-07

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 150

Registration Number: NCT05245838

Locations: 🇦🇺
Paratus Clinical Research Western Sydney, Blacktown, New South Wales, Australia
🇦🇺
Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
🇦🇺
Paratus Clinical Research Central Coast, Kanwal, New South Wales, Australia

and more 1 locations

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Phase 1

Completed

Conditions: End Stage Renal Disease on Hemodialysis (Diagnosis)

Interventions: Drug: HEPLISAV-B®

First Posted Date: 2019-05-02

Last Posted Date: 2024-08-09

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 119

Registration Number: NCT03934736

Locations: 🇺🇸
DaVita Clinical Research or Affiliate, Milwaukee, Wisconsin, United States

DV2-HBV-27: Observational Pregnancy Registry

Active, not recruiting

Conditions: Pregnant

Interventions: Biological: HEPLISAV-B

First Posted Date: 2018-09-10

Last Posted Date: 2023-09-18

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 300

Registration Number: NCT03664648

Locations: 🇺🇸
PPD Registry Office, Recruiting Nationwide, Wilmington, North Carolina, United States

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

Phase 1

Completed

Conditions: Advanced Non Small Cell Lung Cancer

Interventions: Drug: DV281
Drug: DV281 (RP2D)
Device: Breath Actuated Nebulizer
Drug: Approved Anti-PD-1 Inhibitor

First Posted Date: 2017-10-31

Last Posted Date: 2020-06-17

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 26

Registration Number: NCT03326752

Locations: 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸
Ronald Reagan University of California Los Angeles Medical Center, Santa Monica, California, United States

and more 3 locations

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

Terminated

Conditions: Metastatic Melanoma
Head Neck Cancer

Interventions: Drug: SD-101(1)
Drug: SD-101(2)
Biological: SD-101(3)
Biological: Pembrolizumab

First Posted Date: 2015-08-13

Last Posted Date: 2021-08-03

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 241

Registration Number: NCT02521870

Locations: 🇺🇸
Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Georgia Cancer Center - Northside Hospital Central Research Department, Atlanta, Georgia, United States

and more 44 locations

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Phase 1

Terminated

Conditions: B-cell Lymphoma

Interventions: Drug: SD-101
Radiation: Radiation therapy

First Posted Date: 2014-10-16

Last Posted Date: 2020-09-04

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 29

Registration Number: NCT02266147

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Stanford University School of Medicine, Stanford, California, United States

and more 2 locations

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

Phase 3

Completed

Conditions: Healthy

Interventions: Biological: HEPLISAV
Biological: Engerix-B

First Posted Date: 2014-04-21

Last Posted Date: 2019-03-20

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 8374

Registration Number: NCT02117934

Locations: 🇺🇸
Clinical Research Advantage, Inc., Plano, Texas, United States
🇺🇸
Clinical Research Advantage, Inc, Evansville, Indiana, United States
🇺🇸
Radiant Research, Murray, Utah, United States

A Study of the Immune Response to Heplisav in Healthy Older Adults

Phase 1

Completed

Conditions: Hepatitis B

Interventions: Biological: HEPLISAV

First Posted Date: 2013-12-03

Last Posted Date: 2019-03-20

Lead Sponsor: Dynavax Technologies Corporation

Target Recruit Count: 25

Registration Number: NCT01999699

Locations: 🇺🇸
Johnson County Clinical Trials, Lenexa, Kansas, United States

Home Terms & Conditions Privacy Policy